FDMT4D Molecular Therapeutics, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $85M
- 230195% YoY
- Operating margin
- -187.2%
- 100% YoY
- EBITDA
- −$155M
- 15% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$51M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired26% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $18M | $3M | $21M | $37K | $85M | 230195% |
| Operating income | −$71M | −$110M | −$113M | −$188M | −$160M | 15% |
| Net income | −$71M | −$107M | −$101M | −$161M | −$140M | 13% |
| Operating cash flow | −$69M | −$87M | −$76M | −$135M | −$109M | 19% |
| Capex | $9M | $12M | $3M | $4M | $536K | 86% |
| Stock-based comp | $14M | $17M | $20M | $26M | $22M | 16% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 5
- Net
- −$2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $3M | 34 | — |
| FY2024 | $1M | −$7M | 25 | — |
| FY2023 | $10M | $15M | 91 | — |